Can Polygenic Risk Scores Transform Daily Patient Care?
Genomics has transformed oncology and the diagnosis of rare monogenic disorders over the past 25 years. However, genomic discoveries have had little direct impact on routine care for common adult conditions. Genomewide association studies demonstrate that thousands of common genetic variants shape individual disease susceptibility. Consequently, investigators developed polygenic risk scores to aggregate these minute effects into actionable clinical probabilities.
Why Have Polygenic Risk Scores Stalled in Clinical Practice?
Translational barriers have slowed the clinical uptake of genetic risk profiling. First, traditional clinical risk engines already predict cardiovascular and metabolic outcomes reasonably well. Therefore, many clinicians question whether adding genetic data changes overall management. Furthermore, early genetic profiling tools offered limited incremental predictive gain over standard risk calculators. Most studies also focused predominantly on populations of European descent. As a result, performance drops when clinicians apply these algorithms to diverse ancestral cohorts, including South Asian populations. In addition, regulatory frameworks and health insurers demand clear proof that testing improves actual clinical endpoints.
Emerging Clinical Applications in Disease Prevention
Affordable whole-genome sequencing is rapidly dismantling historical cost barriers. Therefore, health systems can now evaluate genetic risks earlier in a patient's lifespan. Specifically, genetic profiling identifies young individuals whose cumulative polygenic vulnerability matches high-penetrance monogenic mutations. For example, clinicians can initiate intensive lipid-lowering therapy or lifestyle interventions decades before coronary plaques develop. Moreover, combining genetic risk with clinical parameters significantly refines disease stratification for diabetes, glaucoma, and common cancers. Consequently, preventive medicine shifts from reactive care to proactive lifetime risk management.
The Synergy of Genetics and Pharmacogenomics
Pharmacogenomics represents another direct avenue for clinical translation. Genetic variations consistently explain why individual patients experience therapeutic failure or severe adverse reactions. For instance, specific alleles dictate the metabolic clearance of antiplatelet drugs, statins, and psychotropic medications. Furthermore, combining disease risk scores with pharmacogenomic testing creates a comprehensive therapeutic blueprint. Clinicians can simultaneously determine both the absolute disease risk and the optimal pharmacological agent. Thus, this integrated approach minimizes medication side effects and maximizes treatment efficacy across diverse clinical settings.
Frequently Asked Questions
Q1: What are polygenic risk scores?
Polygenic risk scores quantify an individual's cumulative genetic susceptibility to common complex diseases. They aggregate the subtle effects of thousands of common genetic variants discovered through genomewide association studies.
Q2: Why have these scores not achieved routine clinical adoption?
Adoption remains limited due to modest incremental benefit over standard clinical risk tools, high test costs, and ancestral bias. Furthermore, clinicians require randomized evidence proving that scores improve patient survival and clinical outcomes.
Q3: How does pharmacogenomics complement disease risk scoring?
Disease scores identify patients who require medical intervention. Meanwhile, pharmacogenomics predicts how those patients will metabolize and tolerate specific drugs, guiding safe and precise prescribing decisions.
References
- Hunter DJ et al. Clinical Uses of Common Genetic Variants Associated with Common Diseases. N Engl J Med. 2026 Sep 24. doi: 10.1056/NEJMra2413201. PMID: 42777243.
- Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224.
- Centers for Disease Control and Prevention. Polygenic Risk Scores in Clinical Practice? Still Making the Case. CDC Genomics and Health Impact Blog. Published July 5, 2022.
